Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy.

Berckmans, Yani; Ceusters, Jolien; Vankerckhoven, Ann; Wouters, Roxanne; Riva, Matteo; Coosemans, An

Berckmans, Yani; Ceusters, Jolien; Vankerckhoven, Ann; Wouters, Roxanne; Riva, Matteo; Coosemans, An.

Afiliación

Berckmans Y; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Ceusters J; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Vankerckhoven A; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Wouters R; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Riva M; Oncoinvent AS, Oslo, Norway.
Coosemans A; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.

Front Immunol ; 14: 1236965, 2023.

Article en En | MEDLINE | ID: mdl-37744323

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica; Inmunoterapia; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Inhibidores de Puntos de Control Inmunológico; Oncología Médica; Investigación

Palabras clave

cancer therapy; chemotherapy; combination treatment; immune checkpoint inhibitors; preclinical models

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Inmunoterapia Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google